IHC - Factor VIII a

The IHC – Factor VIII-Related Antigen (Factor VIIIa) test is an immunohistochemistry (IHC) test used to detect endothelial cell markers in tissue samples. Factor VIII-related antigen, also known as von Willebrand factor (vWF), is a protein found in the lining of blood vessels (endothelial cells). This test is highly valuable in identifying tumors and lesions that originate from blood vessels.

It is mainly used in diagnostic pathology to confirm vascular origin of tumors, especially when evaluating suspected benign or malignant vascular growths. The presence of Factor VIIIa in tissue indicates endothelial differentiation, helping pathologists distinguish vascular tumors from other soft tissue neoplasms.

Benefits of the Test

The Factor VIIIa IHC test provides important diagnostic insights, including:

• Identification of vascular endothelial cells in tissue samples
• Confirmation of vascular tumors such as hemangioma and angiosarcoma
• Differentiation between vascular and non-vascular tumors
• Support in tumor classification and grading
• Improved accuracy in complex soft tissue tumor diagnosis

This marker is often used alongside other endothelial markers such as CD31 and CD34 to increase diagnostic accuracy.

Why Doctors Recommend This Test

Doctors recommend the IHC Factor VIIIa test when a biopsy suggests the possibility of a vascular tumor or when tumor origin is unclear. It is particularly important in cases where imaging and routine histology cannot clearly define the tumor type. Oncologists and pathologists rely on this test to confirm whether abnormal tissue growth is derived from blood vessel lining cells.

It is commonly used in the evaluation of:

• Soft tissue tumors
• Skin lesions with suspected vascular origin
• Liver or organ lesions with vascular characteristics
• Suspected malignant vascular tumors (angiosarcoma)

Preparation Before Test

No specific preparation is required from the patient. The test is performed on previously collected biopsy or surgical tissue samples. Standard biopsy instructions provided by the treating physician should be followed.

Normal Reporting Time

The typical turnaround time for the IHC Factor VIIIa test is 2 to 4 working days, depending on laboratory workflow and staining procedures.

Who Should Take This Test

This test is recommended for:

• Patients with suspected vascular tumors
• Individuals with biopsy showing unclear tumor origin
• Cases of hemangioma or angiosarcoma suspicion
• Soft tissue tumor evaluations
• Oncology diagnostic workups requiring endothelial markers

The Factor VIIIa IHC test is an essential tool in modern pathology for identifying vascular differentiation in tumors. It helps distinguish benign vascular growths from malignant ones and provides clarity in complex diagnostic cases. When combined with other markers, it significantly improves diagnostic precision and supports accurate treatment planning.